Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous mesoangioblast intra-arterial therapy for m.3243A>G mitochondrial myopathy
NL-OMON50120Phase 1Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous mesoangioblasts in Mitochondrial myopathies (MM) and Mitochondriopathy, sponsored by Maastricht University Medical Center+. Primary endpoint: Safety of autologous mesoangioblast administration. Started Nov 2020; status: active, not recruiting.
02
Drugs
autologous mesoangioblasts
03
Conditions
Mitochondrial myopathies (MM)Mitochondriopathy
Beyond the preview
Go deeper on NL-OMON50120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50120.